Synlogic Past Earnings Performance
Past criteria checks 0/6
Synlogic's earnings have been declining at an average annual rate of -4.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 7.8% per year.
Key information
-4.5%
Earnings growth rate
23.6%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 7.8% |
| Return on equity | -351.4% |
| Net Margin | -1,771.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Synlogic makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 3 | -56 | 11 | 30 |
| 31 Mar 24 | 3 | -73 | 13 | 39 |
| 31 Dec 23 | 3 | -57 | 15 | 44 |
| 30 Sep 23 | 1 | -59 | 15 | 47 |
| 30 Jun 23 | 1 | -65 | 16 | 52 |
| 31 Mar 23 | 1 | -66 | 16 | 53 |
| 31 Dec 22 | 1 | -66 | 17 | 52 |
| 30 Sep 22 | 2 | -65 | 17 | 50 |
| 30 Jun 22 | 2 | -63 | 16 | 49 |
| 31 Mar 22 | 2 | -61 | 16 | 48 |
| 31 Dec 21 | 2 | -61 | 15 | 47 |
| 30 Sep 21 | 1 | -60 | 15 | 47 |
| 30 Jun 21 | 0 | -57 | 14 | 44 |
| 31 Mar 21 | 0 | -58 | 14 | 46 |
| 31 Dec 20 | 1 | -59 | 14 | 47 |
| 30 Sep 20 | 2 | -57 | 14 | 47 |
| 30 Jun 20 | 2 | -57 | 15 | 47 |
| 31 Mar 20 | 2 | -54 | 15 | 44 |
| 31 Dec 19 | 2 | -51 | 15 | 42 |
| 30 Sep 19 | 1 | -51 | 15 | 25 |
| 30 Jun 19 | 3 | -48 | 15 | 24 |
| 31 Mar 19 | 3 | -50 | 16 | 25 |
| 31 Dec 18 | 3 | -48 | 16 | 23 |
| 30 Sep 18 | 3 | -48 | 16 | 37 |
| 30 Jun 18 | 1 | -49 | 16 | 36 |
| 31 Mar 18 | 3 | -44 | 14 | 34 |
| 31 Dec 17 | 2 | -40 | 13 | 30 |
| 30 Sep 17 | 2 | -36 | 10 | 28 |
| 30 Jun 17 | 2 | -29 | 9 | 23 |
| 31 Mar 17 | 0 | -24 | 7 | 18 |
| 31 Dec 16 | 0 | -21 | 6 | 15 |
Quality Earnings: 0A8U is currently unprofitable.
Growing Profit Margin: 0A8U is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0A8U is unprofitable, and losses have increased over the past 5 years at a rate of 4.5% per year.
Accelerating Growth: Unable to compare 0A8U's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0A8U is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Return on Equity
High ROE: 0A8U has a negative Return on Equity (-351.4%), as it is currently unprofitable.